Recombinant erythropoietin fusion protein - Merck Serono
Alternative Names: FC EPOLatest Information Update: 08 Apr 2009
At a glance
- Originator Merck Serono
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Anaemia in Switzerland (Parenteral)
- 24 Oct 2007 Phase-I clinical trials in Anaemia in Switzerland (Parenteral)